Hepatitis C Vaccine

Grant number: 1060436 | Funding period: 2014 - 2017

Completed

Abstract

Hepatitis C virus is responsible for over 300,000 deaths per year world wide and in Australia causes 10,000 new cases each year. A vaccine to prevent or treat this infection is not available. The aim of this project is to develop a vaccine that will elicit neutralising antibody and cell mediated immunity against hepatitis C virus. These responses are essential for a prophylactic vaccine to be effective in preventing infection in individuals who are at risk of hepatitis C infection.

Related publications (6)

Scholarly works icon

Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery

D Christiansen, L Earnest-Silveira, B Grubor-Bauk, DK Wijesundara, I Boo, PA Ramsland, E Vincan, HE Drummer, EJ Gowans, J Torresi

2019-12-01

The introduction of directly acting antiviral agents (DAAs) has produced significant improvements in the ability to cure chronic h..

Scholarly works icon

Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine

D Christiansen, L Earnest-Silveira, B Chua, P Meuleman, I Boo, B Grubor-Bauk, DC Jackson, ZY Keck, SKH Foung, HE Drummer, EJ Gowans, J Torresi

2018-12-01

The significant public health problem of Hepatitis C virus (HCV) has been partially addressed with the advent of directly acting a..

Scholarly works icon

Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists

D Christiansen, L Earnest-Silveira, B Chua, I Boo, HE Drummer, B Grubor-Bauk, EJ Gowans, DC Jackson, J Torresi

2018-05-01

The development of an effective preventative hepatitis C virus (HCV) vaccine will reside, in part, in its ability to elicit neutra..

Scholarly works icon

The rationale for a preventative HCV Virus-Like Particle (VLP) Vaccine

J Torresi

2017-11-07

HCV represents a global health problem with ~200 million individuals currently infected, worldwide. With the high cost of antivira..

Scholarly works icon

Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine

L Earnest-Silveira, D Christiansen, S Herrmann, SA Ralph, S Das, EJ Gowans, J Torresi

2016-10-01

A method for the large-scale production of a quadrivalent mammalian cell derived hepatitis C virus-like particles (HCV VLPs) is de..

Scholarly works icon

Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line

L Earnest-Silveira, B Chua, R Chin, D Christiansen, D Johnson, S Herrmann, SA Ralph, K Vercauteren, A Mesalam, P Meuleman, S Das, I Boo, H Drummer, CT Bock, EJ Gowans, DC Jackson, J Torresi

2016-08-01

An effective immune response against hepatitis C virus (HCV) requires the early development of multi-specific class 1 CD8<sup>+</s..

University of Melbourne Researchers